EGFR Lung Cancer 2025: AstraZeneca’s Tagrisso vs J&J’s Rybrevant in Global Trials Highlight Efficacy and Tolerability Trade-Offs

Lung cancer remains one of the world’s deadliest malignancies, accounting for about 12.4% of new cancer cases and causing roughly 1.8 million deaths each year — 18.7% of all cancer-related mortality. Its treatment landscape today straddles a delicate balance: targeted therapies, immunotherapies, and antibody-drug conjugates are changing paradigms, while high-stakes M&A and licensing deals signal how capital sees the next frontier. In 2025, lung cancer biotech is evolving rapidly — globally and regionally, in the lab and the boardroom, in pipelines and partnerships. The year’s narrative is being shaped by recent deals, shifts in R&D strategy, key assets in play, and the evolving research terrain.

Asia’s High EGFR Prevalence Puts Pressure on New Therapies to Match Tagrisso’s Balance of Survival and Tolerability

The lung cancer ground is shifting. In Asia, particularly China and East Asia, trial data and regulatory sensitivity increasingly influence biopharma strategy. In the U.S. and Europe, the focus remains on first-in-class targets, immuno-oncology combinations, and differentiation vs existing standards.

At the 2025 World Lung Congress, one striking “regional tension” emerged: in EGFR-mutated non-small cell lung cancer (NSCLC), new agents must deliver not just efficacy but also tolerability to displace entrenched standards. This is especially critical in Asia, where up to 50% of NSCLC cases carry EGFR mutations, compared with only about 10–15% in Western populations. That higher prevalence makes Asia the world’s largest testing ground for EGFR therapies, but also a market where treatment habits are firmly anchored around osimertinib (Tagrisso, AstraZeneca), the current global first-line standard. 

Osimertinib has set a high bar by combining durable survival benefits with a relatively manageable safety profile. Any challenger must not only improve tumor control but also match or surpass its tolerability in real-world practice — otherwise physicians and payers are unlikely to move away from an established therapy that patients already accept.

FLAURA-2: Tagrisso Plus Chemotherapy Reaches Nearly Four Years OS

The FLAURA-2 trial (N=557) is a global Phase III study testing Tagrisso in combination with platinum-based chemotherapy versus Tagrisso alone. Presented at WCLC 2025, the final analysis reported a median overall survival (OS) of 47.5 months for the combination, compared with 37.6 months for monotherapy. Three-year survival rates reached 63.1% vs 50.9%, and the hazard ratio for death was 0.77 (95% CI: 0.61–0.96, p=0.0202).

These results represent the longest survival ever reported in a global Phase III trial for EGFR-mutated advanced lung cancer. Importantly, the OS benefit was consistent across all prespecified subgroups, even though most patients in the monotherapy arm later received chemotherapy upon progression. The safety trade-off was clear: Grade ≥3 adverse events occurred in 70% of patients on the combination, compared with 34% on Tagrisso alone. Most toxicities were chemotherapy-related, but discontinuation rates remained relatively low (12% vs 7%).

FLAURA-2 therefore confirmed Tagrisso’s role as the backbone therapy in EGFR-mutated NSCLC — either alone or in combination with chemotherapy, depending on patient fitness and preferences.

MARIPOSA: Rybrevant and Lazcluze Aim to Challenge the Standard

The MARIPOSA trial (N≈1,000) is one of the largest Phase III studies ever conducted in this setting. It randomized patients to three arms: Rybrevant (amivantamab) plus Lazcluze (lazertinib), Tagrisso monotherapy, or Lazcluze monotherapy.

At the primary analysis, Rybrevant/Lazcluze significantly improved progression-free survival (23.7 vs 16.6 months, HR 0.70, p<0.001) compared to Tagrisso. By the long-term OS analysis (median follow-up 37.8 months), median survival was not estimable for the Rybrevant/Lazcluze arm versus 36.7 months for Tagrisso, with a hazard ratio of 0.75 (95% CI: 0.61–0.92, p=0.005).

Toxicity, however, was higher: Grade ≥3 adverse events occurred in 80% of patients on the Rybrevant/Lazcluze regimen, compared with 52% for Tagrisso. Rash and venous thromboembolic events were the most notable risks, with prophylactic anticoagulation now recommended. Still, J&J emphasizes a potential biological edge, citing fewer EGFR and MET resistance mutations emerging under the combination than with Tagrisso alone — which may shape sequencing and durability in future treatment lines.

Reference Points for the Field: Efficacy Converges, Patient Experience Becomes the Decider

Together, FLAURA-2 (557 patients) and MARIPOSA (~1,000 patients) now stand as the largest and most definitive EGFR-mutant NSCLC trials to date. Both delivered unprecedented survival outcomes but also underscored a common reality: when efficacy converges, tolerability and patient experience become the deciding factors.

In practice, physicians must balance chemotherapy’s broad toxicity with Rybrevant’s immune-related risks and tailor choices to patient age, comorbidities, and regional practice patterns. In Asia, where EGFR mutations are most prevalent, frontline decisions shape the trajectory for subsequent care.

The emerging data show that the future of EGFR therapy depends not only on survival outcomes but also on how treatment choices balance efficacy with long-term tolerability. New EGFR therapies must extend survival and ensure that patients can live with treatment over the long term. These two trials — different in design but similar in impact — now serve as reference points that define the frontline standard for years to come.

Author

Bernice Lottering